Jpmorgan Chase & CO Alpine Immune Sciences, Inc. Transaction History

Jpmorgan Chase & CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$17.75 - $41.6 $64,166 - $150,384	-3,615 Reduced 10.93%	29,459 $1.17 Million
Q4 2023 Feb 12, 2024	BUY	$8.54 - $20.22 $15,073 - $35,688	1,765 Added 5.64%	33,074 $630,000
Q3 2023 Nov 14, 2023	BUY	$10.13 - $13.98 $50,244 - $69,340	4,960 Added 18.82%	31,309 $358,000
Q2 2023 Aug 11, 2023	SELL	$6.84 - $11.91 $149,112 - $259,638	-21,800 Reduced 45.28%	26,349 $270,000
Q1 2023 May 18, 2023	BUY	$7.0 - $8.75 $126,861 - $158,576	18,123 Added 60.36%	48,149 $371,000
Q1 2023 May 11, 2023	BUY	$7.0 - $8.75 $110,572 - $138,215	15,796 Added 111.0%	30,026 $231,000
Q4 2022 Feb 13, 2023	BUY	$5.45 - $7.35 $19,930 - $26,878	3,657 Added 34.59%	14,230 $105,000
Q3 2022 Nov 14, 2022	BUY	$6.89 - $9.39 $6,228 - $8,488	904 Added 9.35%	10,573 $77,000
Q2 2022 Aug 11, 2022	BUY	$6.71 - $9.52 $4,844 - $6,873	722 Added 8.07%	9,669 $82,000
Q1 2022 May 11, 2022	BUY	$6.41 - $13.89 $10,877 - $23,571	1,697 Added 23.41%	8,947 $80,000
Q4 2021 Feb 10, 2022	BUY	$10.41 - $13.95 $29,043 - $38,920	2,790 Added 62.56%	7,250 $101,000
Q3 2021 Nov 12, 2021	BUY	$8.19 - $11.31 $36,527 - $50,442	4,460 New	4,460 $48,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.